Sign Out
General: Therapy with MG-40 oral suspension for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. These treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, and renal or psychiatric diseases.
Effects on HIV viral replication have not been determined.
Use with caution in patients with a history of thromboembolic disease.
Use In Diabetics: Exacerbation of preexisting diabetes with increased insulin requirements has been reported in association with the use of MG-40.
Use in Women with HIV infections: Although megestrol acetate has been used extensively in women for the treatment of breast and endometrial cancer, however, its use in HIV-infected females has been limited.
Use in Children: Safety and effectiveness in pediatric patients have not been established.
Use in the Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
